Skip to main content
main-content

Breast cancer

07-02-2019 | Breast cancer | News | Article

Celecoxib may be contraindicated for some breast cancer patients

Use of the cyclooxygenase 2 inhibitor celecoxib during neoadjuvant taxane-based chemotherapy is associated with adverse survival outcomes in certain subgroups of patients with breast cancer, shows a post-hoc analysis of the REMAGUS02 trial.

01-02-2019 | Colorectal cancer | News | Article

EMA gives biosimilar bevacizumab positive opinion

Read more on this decision here

24-01-2019 | Breast cancer | News | Article

TILs linked to HER2-positive breast cancer treatment outcomes

Tumour-infiltrating lymphocytes could serve as a prognostic marker in patients with early-stage HER2-positive breast cancer being treated with chemotherapy plus trastuzumab, indicates an analysis of the ShortHER trial comparing 9 weeks of trastuzumab with the standard 1-year regimen.

13-12-2018 | Breast cancer | News | Article

Trastuzumab emtansine targets residual invasive HER2-positive breast cancer

Adjuvant trastuzumab emtansine halves the risk of invasive disease recurrence or death versus trastuzumab in patients with residual invasive human epidermal growth factor receptor 2-positive early breast cancer, researchers report.

07-12-2018 | Breast cancer | Video

PD-L1 in immune cells predicts atezolizumab plus nab-paclitaxel efficacy in metastatic triple-negative breast cancer

Presenting author Leisha Emens outlines exploratory efficacy analysis results from IMpassion130 showing that programmed cell death ligand 1 in immune cells is a robust predictive biomarker for selecting women with metastatic triple-negative breast cancer who may benefit from first-line atezolizumab plus nab-paclitaxel treatment (6:19).

07-12-2018 | Breast cancer | Video

Circulating tumour cell count could aid first-line hormone versus chemotherapy treatment decisions

Francois-Clement Bidard reports findings that circulating tumour cell count could help oncologists choose between first line hormone therapy and chemotherapy in women with oestrogen receptor positive, HER2-negative metastatic breast cancer (3:23).

image credits